3.21
+0(+0.00%)
Currency In USD
| Previous Close | 3.21 |
| Open | 3.18 |
| Day High | 3.26 |
| Day Low | 3.16 |
| 52-Week High | 4.72 |
| 52-Week Low | 2.21 |
| Volume | 2.54M |
| Average Volume | 854,304 |
| Market Cap | 608.27M |
| PE | -7.47 |
| EPS | -0.43 |
| Moving Average 50 Days | 3.73 |
| Moving Average 200 Days | 3.45 |
| Change | 0 |
If you invested $1000 in Arbutus Biopharma Corporation (ABUS) 10 years ago, it would be worth $243.37 as of December 21, 2024 at a share price of $3.21. Whereas If you bought $1000 worth of Arbutus Biopharma Corporation (ABUS) shares 5 years ago, it would be worth $1,167.27 as of December 21, 2024 at a share price of $3.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
GlobeNewswire Inc.
Nov 26, 2024 12:30 PM GMT
WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for p
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
GlobeNewswire Inc.
Nov 15, 2024 4:02 PM GMT
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved functional cure Data to be presented in late-breaker p
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
GlobeNewswire Inc.
Nov 15, 2024 4:01 PM GMT
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously 23% of participants receiving imdusiran, VTP-300 and low-dose nivoluma